These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 23982694)
21. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial. Kotlyar E; Keogh AM; Thavapalachandran S; Allada CS; Sharp J; Dias L; Muller D Heart Lung Circ; 2005 Dec; 14(4):245-51. PubMed ID: 16360994 [TBL] [Abstract][Full Text] [Related]
22. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. Sun Z; Fu Q; Cao L; Jin W; Cheng L; Li Z PLoS One; 2013; 8(1):e55124. PubMed ID: 23383076 [TBL] [Abstract][Full Text] [Related]
23. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial. Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489 [TBL] [Abstract][Full Text] [Related]
24. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798 [TBL] [Abstract][Full Text] [Related]
25. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Guru V; Fremes SE Clin Nephrol; 2004 Aug; 62(2):77-83. PubMed ID: 15356963 [TBL] [Abstract][Full Text] [Related]
26. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study. Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691 [TBL] [Abstract][Full Text] [Related]
27. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial. Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645 [TBL] [Abstract][Full Text] [Related]
29. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. Marenzi G; Assanelli E; Marana I; Lauri G; Campodonico J; Grazi M; De Metrio M; Galli S; Fabbiocchi F; Montorsi P; Veglia F; Bartorelli AL N Engl J Med; 2006 Jun; 354(26):2773-82. PubMed ID: 16807414 [TBL] [Abstract][Full Text] [Related]
30. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432 [TBL] [Abstract][Full Text] [Related]
31. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial. Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264 [TBL] [Abstract][Full Text] [Related]
32. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497 [TBL] [Abstract][Full Text] [Related]
33. N-acetylcysteine for the prevention of contrast-induced nephropathy in the emergency department. Hsu TF; Huang MK; Yu SH; Yen DH; Kao WF; Chen YC; Huang MS Intern Med; 2012; 51(19):2709-14. PubMed ID: 23037460 [TBL] [Abstract][Full Text] [Related]
34. Cystatin C and creatinine as markers for radiocontrast-induced nephropathy in patients treated with N-acetylcysteine. Merkle M; Sauter M; Argirov M; Wörnle M Ren Fail; 2010 Jan; 32(1):85-90. PubMed ID: 20113272 [TBL] [Abstract][Full Text] [Related]
35. Should acetylcysteine be used to prevent contrast induced nephropathy? Izcovich A; Rada G Medwave; 2015 Apr; 15(3):e6122. PubMed ID: 25918998 [TBL] [Abstract][Full Text] [Related]
36. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. Bagshaw SM; Ghali WA BMC Med; 2004 Oct; 2():38. PubMed ID: 15500690 [TBL] [Abstract][Full Text] [Related]
37. Review of contrast-induced nephropathy and current use of N-acetylcysteine (NAC). Anwar M; Ledger S CANNT J; 2005; 15(1):33-8,quiz 38-9. PubMed ID: 15909775 [No Abstract] [Full Text] [Related]
38. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367 [TBL] [Abstract][Full Text] [Related]